Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: Implications for its utilization in assessing malignant lesions

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 53, Issue 1, 2009, Pages 9-16

  Basu, S ^a   Kung, J ^a   Houseni, M ^a   Zhuang, H ^a   Tidmarsh, G F ^a   Alavi, Abass ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Fluorodeoxyglucose, F18; Lung neoplasms, radionuclide imaging; Neoplasms; Radiopharmaceuticals

Indexed keywords

FLUORODEOXYGLUCOSE;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CASE REPORT; DRUG BLOOD LEVEL; DRUG UPTAKE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM CANCER; POSITRON EMISSION TOMOGRAPHY; WHOLE BODY IMAGING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 65749100958     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-12.
2. Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7.
3. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999;26:1345-8.
4. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871-5.
5. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002;32:293-321.
6. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005;46:1819-24.
7. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 2006;47:1440-6.
8. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226-30.
9. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003;44:1775-83.
10. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006;47:633-8.
11. 18F] fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun 2004;25:819-23.
12. Basu S, Alavi A. Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging 2007;34:1527-9.
13. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MAA. PET study of 18-FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30.